221 CRESCENT STREET, WALTHAM, MA
Spyre Therapeutics Enters Underwriting Agreement for $350M Offering
Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
News, Material Contracts
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q2
Q1
FY 2024
Q3
Amended Annual Report
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence